SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
This marks the first partnership between Pfizer and Cipla in India
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The state-of-the-art facility is expected to be commissioned over the next three years
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
The update promises to revolutionize laboratory workflows by optimizing resources
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
Subscribe To Our Newsletter & Stay Updated
